2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 001

Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System
Abstract Number: 002

Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression
Abstract Number: 003

Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis
Abstract Number: 004

Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression
Abstract Number: 005

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Abstract Number: 006

Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic
Abstract Number: 007

Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis
Abstract Number: 008

Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Abstract Number: 009

The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
Abstract Number: 010

Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation
Abstract Number: 011

The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Abstract Number: 012

Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances
Abstract Number: 013

Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 014

Characterizing Lupus in African American Children in Southern United States
Abstract Number: 015

Epigenetically-Distinct B Cell Profiles Pre- and Post-Induction Therapy in Pediatric Lupus

1
2
3
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].